José Alain Sahel, MD: Pathway Toward Vision Restoration, Artificial Vision, Artificial Retina, Optogenetics | CMU RI Seminar

11 February 2017

share this:

Link to video on YouTube

Abstract: “Progress in ophthalmology over the past decade moved preclinical data to clinical proof-of-concept studies bringing innovative therapeutic strategies to the market. Diseases such as retinitis pigmentosa (RP) and age-related macular degeneration (AMD) destroy photoreceptors but leave intact and functional a significant number of inner retinal cells. Retinal prostheses have demonstrated ability to reactivate the remaining retinal circuits at the level of bipolar or ganglion cells, after the photoreceptor loss. Recent clinical trials have demonstrated partial restoration of vision in blind people by epiretinal (Second Sight Medical Products, Pixium Vision) and subretinal (Retina Implant AG) implants, in clinical trials and practice now. Despite a limited number of electrodes, some patients were even able to read words and recognize high-contrast objects. Currently, researchers at the Stanford University and Pixium Vision in collaboration with Institut de la Vision develop a wirelessly powered photovoltaic prosthesis in which each pixel of the subretinal array directly converts patterned pulsed near-infrared light projected from video goggles into local electric current to stimulate the nearby retinal neurons. A new asynchronous dynamic visual sensor whose function mimics photoreceptor and retinal cell responses is also under development. Optogenetics (currently under preclinical evaluation in primates) and cell therapy (ongoing first safety and tolerability clinical trials with hESC- and iPSCs-derived RPE) provide alternative approaches for vision restoration in patients with advanced stages of retinal degeneration. Combination of different therapeutic strategies may offer enhanced therapeutic effectiveness and more efficient ways to save vision. These new therapeutic tools call for identification of appropriate patient selection criteria and methods to evaluate treatments’ efficiency and assess the real benefit experienced by the patients.”

John Payne

Related posts :

Breaking through the mucus barrier

A capsule that tunnels through mucus in the GI tract could be used to orally administer large protein drugs such as insulin.
02 October 2022, by

Women in Tech leadership resources from IMTS 2022

There’ve been quite a few events recently focusing on Women in Robotics, Women in Manufacturing, Women in 3D Printing, in Engineering, and in Tech Leadership. One of the largest tradeshows in the US is IMTS 2022. Here I bring you some resources shared in the curated technical content and leadership sessions.
29 September 2022, by and

MIT engineers build a battery-free, wireless underwater camera

The device could help scientists explore unknown regions of the ocean, track pollution, or monitor the effects of climate change.
27 September 2022, by

How do we control robots on the moon?

In the future, we imagine that teams of robots will explore and develop the surface of nearby planets, moons and asteroids - taking samples, building structures, deploying instruments.
25 September 2022, by , and

Have a say on these robotics solutions before they enter the market!

We have gathered robots which are being developed right now or have just entered the market. We have set these up in a survey style consultation.
24 September 2022, by

Shelf-stocking robots with independent movement

A robot that helps store employees by moving independently through the supermarket and shelving products. According to cognitive robotics researcher Carlos Hernández Corbato, this may be possible in the future. If we engineer the unexpected.
23 September 2022, by

©2021 - ROBOTS Association


©2021 - ROBOTS Association